Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

Precigen (Nasdaq: PGEN) will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026.

Rhea-AI Summary

Precigen (Nasdaq: PGEN) will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. A conference call to discuss results is scheduled for 4:30 PM ET.

Dial-in details include 1-800-836-8184 (North America) and 1-646-357-8785 (International). Event details are available in the Events & Presentations section at the company website.

Argus Mar 12 session

-4.09% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – PGEN

On Mar 12, the first trading day after this news, PGEN closed 4.09% below the previous close.

Data tracked by StockTitan Argus for the Mar 12 session.

Key Figures

Earnings release date: March 25, 2026 Conference call time: 4:30 PM ET Current share price: $3.51 +4 more

Earnings release date

March 25, 2026

Full year 2025 financial results and business update

Conference call time

4:30 PM ET

Full year 2025 results discussion

Current share price

$3.51

Price before full-year 2025 earnings-date announcement

200-day MA

$3.32

Pre-news trend reference level

Dial-in North America

1-800-836-8184

Access number for earnings conference call

Dial-in International

1-646-357-8785

Access number for earnings conference call

Early dial-in window

10–15 minutes

Requested lead time before scheduled call

Previous Earnings date Reports

1 past event · Latest: Nov 06

Same Type 1 event

1. Nov 06

   Earnings date notice

   24h Move

   -0.5%

   Announced Q3 2025 results date and conference call logistics for investors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biopharmaceutical, immuno-oncology, autoimmune disorders, infectious diseases, +1 more

5 terms

biopharmaceutical medical

"a commercial-stage biopharmaceutical company specializing in the advancement"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

immuno-oncology medical

"across its core therapeutic areas of immuno-oncology, autoimmune disorders, and"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

autoimmune disorders medical

"therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and"

Autoimmune disorders are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs instead of protecting them, causing chronic inflammation and damage. For investors, they matter because they drive demand for long-term treatments, influence the commercial prospects of drugs and diagnostic tests, and affect healthcare costs and regulatory attention—think of the immune system as a home security system that wrongly targets the house it’s supposed to protect.

infectious diseases medical

"areas of immuno-oncology, autoimmune disorders, and infectious diseases."

Infectious diseases are illnesses caused by germs—like bacteria, viruses, fungi or parasites—that can spread between people, animals or through contaminated surfaces. For investors they matter because outbreaks and ongoing transmission change demand for medical treatments, vaccines and diagnostics, alter healthcare costs and regulatory focus, and can disrupt supply chains and consumer behavior much like a sudden storm changes travel and commerce.

forward-looking statements regulatory

"Cautionary Statement Regarding Forward-Looking Statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.

The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.

Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision^®
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com

Media Contact:
Donelle M. Gregory
press@precigen.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-full-year-2025-financial-results-and-provide-business-updates-on-march-25-302710140.html

SOURCE Precigen, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Precigen (PGEN) release its full year 2025 financial results?

Precigen will release full year 2025 results on March 25, 2026. According to the company, results and business updates will be provided that day and discussed on a conference call at 4:30 PM ET.

How can investors join the Precigen (PGEN) March 25, 2026 conference call?

Investors can join by dialing 1-800-836-8184 (North America) or 1-646-357-8785. According to the company, participants should dial in 10–15 minutes early to ensure timely connection to the 4:30 PM ET call.

Where can I find the Precigen (PGEN) event details and webcast for the March 25 announcement?

Event details and access information are posted in the Events & Presentations section of the company website. According to the company, investors can visit the investor events page for links and supplemental materials.

What will the Precigen (PGEN) March 25, 2026 call cover for shareholders?

The call will cover full year 2025 financial results and business updates at 4:30 PM ET. According to the company, management will discuss performance and may address investor questions during the conference call.

What time should participants dial in for the Precigen (PGEN) March 25 conference call?

Participants are asked to dial in 10–15 minutes before the scheduled 4:30 PM ET start. According to the company, this helps facilitate timely connection and a smooth start to the conference call.